We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

NYSE American - Delayed Quote USD

Scorpius Holdings, Inc. (SCPX)

0.7159

-0.0041

(-0.57%)

At close: November 1 at 4:00 PM EDT

0.7700

+0.05

(+7.56%)

Pre-Market: 7:34 AM EST

Key Events

Loading Chart for SCPX

9/21 12:03 PM

DELL

Previous Close 0.7200
Open 0.7400
Bid --
Ask --
Day's Range 0.7000 - 0.7581
52 Week Range 0.0200 - 8.1100
Volume 128,349
Avg. Volume 137,603
Market Cap (intraday) 2.231M
Beta (5Y Monthly) -0.31
PE Ratio (TTM) --
EPS (TTM) -181.0400
Earnings Date Nov 18, 2024 - Nov 22, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 5.00

Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services. The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024. Scorpius Holdings, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.

www.scorpiusbiologics.com

82

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Scorpius Holdings Announces Collaboration with Celltheon Corporation, a U.S.-Based Cell Line Development Company; First Client Signed Under New Partnership Agreement

Scorpius Holdings Announces Collaboration with Celltheon Corporation, a U.S.-Based Cell Line Development Company; First Client Signed Under New Partnership Agreement

Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected to Save Over $2 Million Annually

Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected to Save Over $2 Million Annually

Scorpius Partners with Biotech Firm to Boost U.S. Biomanufacturing Capabilities

Scorpius Partners with Biotech Firm to Boost U.S. Biomanufacturing Capabilities

Scorpius Holdings Announces Partnership with U.S. Biotech Company

Scorpius Holdings Announces Partnership with U.S. Biotech Company

Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats

Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats

Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities

Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities

Scorpius Holdings Commends the U.S. House of Representatives’ Passage of the BIOSECURE Act

Scorpius Holdings Commends the U.S. House of Representatives’ Passage of the BIOSECURE Act

Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA

Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA

Scorpius Holdings CEO Provides Corporate Update; Highlights Expanding Sales Pipeline, Enhanced Manufacturing Capabilities, and Path Toward Positive Cash Flow

Scorpius Holdings CEO Provides Corporate Update; Highlights Expanding Sales Pipeline, Enhanced Manufacturing Capabilities, and Path Toward Positive Cash Flow

Scorpius Holdings Achieves 16% Year-Over-Year Increase in Revenue for the Second Quarter of 2024

Scorpius Holdings Achieves 16% Year-Over-Year Increase in Revenue for the Second Quarter of 2024

Scorpius Holdings, Inc. Announces Closing of Public Offering

Scorpius Holdings, Inc. Announces Closing of Public Offering

Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SCPX

62.70%

S&P 500

20.10%

1-Year Return

SCPX

93.49%

S&P 500

36.60%

3-Year Return

SCPX

86.59%

S&P 500

24.39%

5-Year Return

SCPX

80.70%

S&P 500

88.60%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Scorpius Holdings, Inc.

0.7159

-0.57%

Mkt Cap 2.231M

Industry Biotechnology

OKYO Pharma Limited

1.2000

+0.84%

Mkt Cap 40.604M

Industry Biotechnology

FibroBiologics, Inc.

3.1800

+5.30%

Mkt Cap 112.124M

Industry Biotechnology

Creative Medical Technology Holdings, Inc.

4.0200

-2.90%

Mkt Cap 7.029M

Industry Biotechnology

Quoin Pharmaceuticals, Ltd.

0.7584

+1.51%

Mkt Cap 3.83M

Industry Biotechnology

NovaBay Pharmaceuticals, Inc.

0.7500

+4.75%

Mkt Cap 3.664M

Industry Biotechnology

Tiziana Life Sciences Ltd

0.9373

-3.87%

Mkt Cap 97.313M

Industry Biotechnology

60 Degrees Pharmaceuticals, Inc.

0.7828

+1.53%

Mkt Cap 1.458M

Industry Biotechnology

TransCode Therapeutics, Inc.

0.4800

+3.23%

Mkt Cap 8.288M

Industry Biotechnology

Protagenic Therapeutics, Inc.

0.6082

-0.13%

Mkt Cap 2.717M

Industry Biotechnology

Qualigen Therapeutics, Inc.

0.0984

-0.20%

Mkt Cap 2.698M

Industry Biotechnology

Valuation Measures

    Annual 

As of 11/1/2024

Market Cap

2.23M
Enterprise Value

16.60M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

0.01
Price/Book (mrq)

0.09
Enterprise Value/Revenue

1.69
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-32.03%
Return on Equity (ttm)

-91.85%
Revenue (ttm)

9.85M
Net Income Avi to Common (ttm)

-29.57M
Diluted EPS (ttm)

-181.0400

Balance Sheet and Cash Flow

Total Cash (mrq)

1.51M
Total Debt/Equity (mrq)

72.60%
Levered Free Cash Flow (ttm)

-16.05M

Earnings Per Share

Consensus EPS

Revenue vs. Earnings

Revenue 759.94k

Earnings -8.87M

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Analyst Price Targets

5.00

5.00 Average

0.7159 Current

5.00 High

SCPX does not have Company Insights

VHAI Vocodia Holdings Corp.

0.0077

-4.38%

BURU Nuburu, Inc.

0.5100

+13.33%

GWAV Greenwave Technology Solutions, Inc.

0.3924

-5.45%

ONCO Onconetix, Inc.

2.9000

+0.35%

CTNT Cheetah Net Supply Chain Service Inc.

2.5800

-8.99%

CRKN Crown Electrokinetics Corp.

0.9595

+0.02%

AKAN Akanda Corp.

0.7490

+3.00%

ZCAR Zoomcar Holdings, Inc.

5.05

-17.75%

NCPL Netcapital Inc.

1.5300

0.00%

STSS Sharps Technology, Inc.

2.8756

-0.84%

PEGY Pineapple Energy Inc.

3.9700

+0.76%

KITT Nauticus Robotics, Inc.

1.3200

-3.65%

ONMD OneMedNet Corporation

0.8120

-5.47%

TPET Trio Petroleum Corp.

0.1232

-3.67%

BNZI Banzai International, Inc.

2.4400

0.00%

SVMH SRIVARU Holding Limited

0.0248

-19.22%